What is OneSkin?
OneSkin is a research-driven biotech company dedicated to revolutionizing skin health and longevity. Founded by four female scientists, the brand prioritizes scientific discovery, leading to the development of its proprietary ingredient, OS-01. This peptide has been scientifically validated to reverse the biological age of skin by targeting cellular damage and dysfunction at a molecular level. OneSkin's product line, including its OS-01 Topical Supplements, is designed to enhance skin cell functionality and promote optimal skin longevity, positioning the company as a leader in the science-backed skincare market.
How much funding has OneSkin raised?
OneSkin has raised a total of $20M across 1 funding round:
Other Financing Round
$20M
Other Financing Round (2025): $20M with participation from Prelude Growth Partners
Key Investors in OneSkin
Prelude Growth Partners
Prelude Growth Partners is a venture capital firm focused on partnering with disruptive consumer brands, particularly in sectors like luxury clean beauty and clinical skincare. Their investment in OneSkin indicates a strategic alignment with innovative companies aiming to capture a significant market share through advanced product offerings.
What's next for OneSkin?
With its latest major strategic investment, OneSkin is poised for significant expansion and further research and development. The substantial capital will likely fuel the scaling of its operations, enhance its product innovation pipeline, and broaden its market reach. This funding round, characterized as enterprise-level, suggests a strategic partnership aimed at accelerating OneSkin's mission to redefine aging through advanced skincare science. The company's focus on scientific validation and proprietary technology provides a strong foundation for future growth and market leadership in the competitive beauty and wellness sector.
See full OneSkin company page
